Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Malignancy × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 42 Small Cell Lung Carcinoma 19 Sarcoma 15 Breast Neoplasms 13 Lung Neoplasms 9 Stomach Neoplasms 8 Neoplasms 8 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Hepatocellular 7 Thyroid Neoplasms 6 Ovarian Neoplasms 6 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 5 NSCLC 5 Uterine Cervical Neoplasms 4 Nasopharyngeal Carcinoma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma 4 Neoplasm Metastasis 3 Glioma 3 Endometrial Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2

Interventions

tremelimumab 1 durvalumab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡